EKF Diagnostics Holdings Plc (EKF) - Total Assets
Based on the latest financial reports, EKF Diagnostics Holdings Plc (EKF) holds total assets worth GBX81.14 Million GBX (≈ $9.87K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EKF Diagnostics Holdings Plc - Total Assets Trend (2001–2025)
This chart illustrates how EKF Diagnostics Holdings Plc's total assets have evolved over time, based on quarterly financial data. Also see EKF market cap overview for the company's overall valuation and market capitalisation.
EKF Diagnostics Holdings Plc - Asset Composition Analysis
Current Asset Composition (December 2025)
EKF Diagnostics Holdings Plc's total assets of GBX81.14 Million consist of 38.1% current assets and 62.0% non-current assets. Review how much debt does EKF Diagnostics Holdings Plc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 19.5% |
| Accounts Receivable | GBX6.04 Million | 7.5% |
| Inventory | GBX8.30 Million | 10.2% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX3.75 Million | 4.6% |
| Goodwill | GBX24.14 Million | 29.8% |
Asset Composition Trend (2001–2025)
This chart illustrates how EKF Diagnostics Holdings Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest EKF Diagnostics Holdings Plc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EKF Diagnostics Holdings Plc's current assets represent 38.1% of total assets in 2025, an increase from 3.8% in 2001.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, up from 0.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 95.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 29.8% of total assets.
EKF Diagnostics Holdings Plc Competitors by Total Assets
Key competitors of EKF Diagnostics Holdings Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
USA | $1.81 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Eurobio Scientific SA
PA:ALERS
|
France | €259.11 Million |
|
Profound Medical Corp
TO:PRN
|
Canada | CA$62.28 Million |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
EKF Diagnostics Holdings Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.16 | 4.44 | 2.26 |
| Quick Ratio | 3.04 | 3.29 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX23.45 Million | GBX22.11 Million | GBX24.54 Million |
EKF Diagnostics Holdings Plc - Advanced Valuation Insights
This section examines the relationship between EKF Diagnostics Holdings Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | GBX81.14 Million |
| Market Capitalization | $1.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values EKF Diagnostics Holdings Plc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: EKF Diagnostics Holdings Plc's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for EKF Diagnostics Holdings Plc (2001–2025)
The table below shows the annual total assets of EKF Diagnostics Holdings Plc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX81.14 Million ≈ $9.87K |
-0.74% |
| 2024-12-31 | GBX81.75 Million ≈ $9.95K |
+1.11% |
| 2023-12-31 | GBX80.85 Million ≈ $9.84K |
-9.45% |
| 2022-12-31 | GBX89.29 Million ≈ $10.86K |
-22.44% |
| 2021-12-31 | GBX115.12 Million ≈ $14.01K |
+13.68% |
| 2020-12-31 | GBX101.27 Million ≈ $12.32K |
+16.23% |
| 2019-12-31 | GBX87.13 Million ≈ $10.60K |
+7.06% |
| 2018-12-31 | GBX81.38 Million ≈ $9.90K |
+5.47% |
| 2017-12-31 | GBX77.16 Million ≈ $9.39K |
-6.40% |
| 2016-12-31 | GBX82.43 Million ≈ $10.03K |
+14.67% |
| 2015-12-31 | GBX71.89 Million ≈ $8.75K |
-47.05% |
| 2014-12-31 | GBX135.78 Million ≈ $16.52K |
+123.60% |
| 2013-12-31 | GBX60.72 Million ≈ $7.39K |
+8.98% |
| 2012-12-31 | GBX55.72 Million ≈ $6.78K |
-5.14% |
| 2011-12-31 | GBX58.73 Million ≈ $7.15K |
+63.24% |
| 2010-12-31 | GBX35.98 Million ≈ $4.38K |
+462.44% |
| 2009-12-31 | GBX6.40 Million ≈ $778.33 |
+11.48% |
| 2008-12-31 | GBX5.74 Million ≈ $698.15 |
+3.11% |
| 2007-12-31 | GBX5.57 Million ≈ $677.10 |
+7.83% |
| 2006-12-31 | GBX5.16 Million ≈ $627.94 |
+6.57% |
| 2005-12-31 | GBX4.84 Million ≈ $589.25 |
-27.25% |
| 2004-12-31 | GBX6.66 Million ≈ $809.96 |
+5.23% |
| 2003-12-31 | GBX6.33 Million ≈ $769.69 |
+1033.69% |
| 2003-06-30 | GBX558.00K ≈ $67.89 |
-91.32% |
| 2002-12-31 | GBX6.43 Million ≈ $782.59 |
+18.06% |
| 2001-12-31 | GBX5.45 Million ≈ $662.86 |
-- |
About EKF Diagnostics Holdings Plc
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit rea… Read more